---
title: "Aardvark Therapeutics, Inc. (AARD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AARD.US.md"
symbol: "AARD.US"
name: "Aardvark Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T06:51:20.322Z"
locales:
  - [en](https://longbridge.com/en/quote/AARD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AARD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AARD.US.md)
---

# Aardvark Therapeutics, Inc. (AARD.US)

## Company Overview

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [aardvarktherapeutics.com](https://aardvarktherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.36 | 120 | - | - | - |
| PB | 1.10 | 54 | 2.31 | 1.73 | 1.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 50% |
| Hold | 4 | 33% |
| Underweight | 1 | 8% |
| Sell | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.37 |
| Highest Target | 45.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AARD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AARD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AARD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AARD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**